The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)

Affiliations

• ¹ Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
• ² Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
• ³ Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
• ⁴ Department of Cardiovascular Medicine, Shinshu University Hospital, Matsumoto, Japan.
• ⁵ Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
• ⁶ Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
• ⁷ British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
• ⁸ Amgen, Inc., Thousand Oaks, CA, USA.
• ⁹ Cytokinetics, Inc., South San Francisco, CA, USA.
• ¹⁰ Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.